Bahrt Kenneth 4
4 · Oncobiologics, Inc. · Filed Oct 24, 2018
Insider Transaction Report
Form 4
Bahrt Kenneth
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2018-10-22+450,000→ 450,000 totalExercise: $0.90Exp: 2028-10-22→ Common Stock (450,000 underlying)
Footnotes (1)
- [F1]The shares underlying the option shall vest in four equal installments beginning on October 22, 2019 such that the option shall be vested in full on October 22, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in certain circumstances as provided in the Issuer's 2015 Equity Incentive Plan.